Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery

Spine

Volumn 34, Issue 19, 2009, Pages 2096-2103

  Berenholtz, Sean M ^a   Pham, Julius Cuong ^a   Garrett Mayer, Elizabeth ^b   Atchison, Christine W ^a   Kostuik, John P ^a   Cohen, David B ^a   Nundy, Shantanu ^a   Dorman, Todd ^a   Ness, Paul M ^a   Klag, Michael J ^a   Pronovost, Peter J ^a   Kebaish, Khaled M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antifibrinolytic agents; Blood transfusions; Orthopedic procedures; Randomized controlled trial

Indexed keywords

AMINOCAPROIC ACID; PLACEBO;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INTENSIVE CARE UNIT; KYPHOSCOLIOSIS; KYPHOSIS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; PSEUDARTHROSIS; RANDOMIZED CONTROLLED TRIAL; SCOLIOSIS; SPINE SURGERY; THROMBOEMBOLISM; THROMBOSIS; VERTEBRAL CANAL STENOSIS;

6-AMINOCAPROIC ACID; ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION, AUTOLOGOUS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOSTASIS, SURGICAL; HUMANS; INTENSIVE CARE; LENGTH OF STAY; MALE; MIDDLE AGED; OSTEOTOMY; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; SPINAL FUSION; SPINE; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349116975     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181b1fab2     Document Type: Article

References (13)

1. Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion Medicine. First of 2 parts: blood transfusion. N Engl J Med 1999;340:438-447
2. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med 2006;355:1303-1305
3. Spahn DR, Casutt M. Eliminating blood transfusions: new aspects and perspectives. Anesthesiology 2000;93:242-255
4. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007;356:2301-2311
5. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007:17:CD001886.
6. Thompson GH, Florentino-Pineda I, Poe-Kochert C. The role of amicar in decreasing perioperative blood loss in idiopathic scoliosis. Spine 2005; 30(suppl 17):S94-9.
7. Urban MK, Beckman J, Gordon M, et al. The efficancy of antifbrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery. Spine 2001;26:1152-1156
8. Amar D, Grant FM, Zhang H, et al. Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery. Anesthesiology 2003;98:337-342
9. Florentino-Pineda I, Thompson GH, Poe-Kochert C, et al. The effect of amicar on perioperative blood loss in idiopathic scoliosis: the results of a prospective, randomized double-blind study. Spine 2004;29:233-238
10. Florentino-Pineda I, Blakemore LC, Thompson GH, et al. The effect of epsilon-aminocaproic acid on perioperative blood loss in patients with ideo-pathic scoliosis undergoing posterior spinal fusion: a preliminary prospective study. Spine 2001;26:1147-1151
11. Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001;1:CD001886.
12. Ioannidis JP, Haidich A, Pappa M, et al. Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized Studies. JAMA 2001;286:821-830
13. Carson JL, Altman DG, Duff A, et al. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion 1999;39:694-700.